QualityStocksNewsBreaks – VolitionRx (NYSE American: VNRX) Signs LOI With Missionpharma to Explore Global Development and Commercialization of NETosis Diagnostic Test
VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, announced that it has signed a nonbinding letter of intent ("LOI") with Denmark-based Missionpharma A/S to explore the development and global commercialization of its prototype lateral flow technology ("LFT") for detecting NETosis, a process associated with inflammation. The collaboration will initially focus on evaluating the finger-prick diagnostic test for neonatal sepsis, with potential applications in low- and middle-income countries and humanitarian emergency settings. Missionpharma, which supplies healthcare products to United Nations agencies, government health ministries and other institutions, could support low-cost manufacturing, clinical studies and distribution. The agreement follows Volition's recent…
